Document
type: Class

Anualidad
type: Class

Information Content Entity
type: Class

Continuant
type: Class

Conference Poster
type: Class

2022
type: Class

Entity
type: Class

Congress communication
type: Class

Generically Dependent Continuant
type: Class

individual
type: Document
rights: termsOfUse
date: 2026-08-31T21:39:20
publisher: Perceptions of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) From Patients in the CAB + RPV Implementation Study in European Locations (CARISEL)
label: RDF description of Perceptions of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) From Patients in the CAB + RPV Implementation Study in European Locations (CARISEL) - http://research.umh.es/vivo/pub/comunicacion/237291

Perceptions of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) From Patients in the CAB + RPV Implementation Study in European Locations (CARISEL)
type: 2022
type: Congress communication
type: Document
RO_0002353: HIV DRUG THERAPY GLASGOW 2022
most specific type: Conference Poster
type: Thing
related by: Autor:36736-Comunicación:237291
type: Entity
type: Information Content Entity
most specific type: Congress communication
type: Generically Dependent Continuant
most specific type: 2022
type: Continuant
ARG_2000028: 237291 vcard
type: Anualidad
type: Conference Poster
included: Medicina Clínica 2022
date time value: 237291 pubdate

HIV DRUG THERAPY GLASGOW 2022
type: BFO_0000015
type: Conference
type: Thing
type: Anualidad
type: Event
type: Entity
type: BFO_0000003
RO_0002234: Perceptions of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) From Patients in the CAB + RPV Implementation Study in European Locations (CARISEL)
type: 2022

Autor:36736-Comunicación:237291
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Perceptions of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) From Patients in the CAB + RPV Implementation Study in European Locations (CARISEL)

Medicina Clínica 2022
type: 2022
type: Anualidad
type: DepartmentReport
type: Thing
type: ResearchReport
includes: Perceptions of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) From Patients in the CAB + RPV Implementation Study in European Locations (CARISEL)